OMEICOS Therapeutics receives 2.5 million euros in grant funding

Funding to support the development of OMT-28 in mitochondrial diseases through a Phase 2a clinical study

25-Jul-2023 - OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced that the Company has received a significant grant by the German Federal Ministry of Education and Research ...

OMEICOS Therapeutics Closes €17m Series C Financing

Advancing lead candidate towards pivotal trials

05-Nov-2018 - OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new ...

OMEICOS Secures Extension of Series B Financing Round

09-Oct-2017 - OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing by ...

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A

20-Apr-2015 - OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were ...